

The quantitative haemodynamic effect of levosimendan, dobutamine, and milrinone in heart failure patients: a meta-analysis

Vincenzo Nuzzi ^{1,2,*}, Cristina Madaudo³, Paolo Manca¹, Antonio Cannata ⁴, Giuseppe Raffa ^{5,6}, Massimiliano Mulè¹, Stefano Cannata ⁷, Eluisa La Franca¹, Calogera Pisano^{5,6}, Manlio Cipriani¹, and Roberto Lorusso ²

¹Clinical Cardiology and Heart Failure Unit, IRCCS-ISMETT (Mediterranean Institute for Transplantation and Specialized Therapies), Via Tricomi 5, Palermo 90127, Italy; ²Cardiothoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands; ³Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) University of Palermo, Italy; ⁴School of Cardiovascular Medicine and Sciences, King's College London, London, UK; ⁵IRCCS-ISMETT (Mediterranean Institute for Transplantation and Specialized Therapies), Palermo, Italy; ⁶Department of Precision Medicine in Medical Surgical and Critical Area (Me.Pre.C.C.), University of Palermo, Palermo 90134, Italy; and ⁷Unit of Interventional Cardiology, IRCCS-ISMETT (Mediterranean Institute for Transplantation and Specialized Therapies), Palermo, Italy

Received 5 September 2025; revised 1 December 2025; accepted 20 April 2026; online publish-ahead-of-print 24 April 2026

Abstract

Introduction

Inotropic therapy is a cornerstone of medical treatment for patients with low-output heart failure (HF). We aimed to investigate the quantitative effect of specific inotropic drugs on invasive haemodynamics.

Methods

This meta-analysis assessed the haemodynamic effects of dobutamine, levosimendan, and milrinone in patients with low-output HF. Only studies using invasive haemodynamic assessment were included. The primary outcome was the quantitative change in variables such as cardiac index, pulmonary artery wedge pressure, mean pulmonary artery pressure, mean arterial pressure (MAP), pulmonary and systemic vascular resistance (before and after administration of each drug). Quality was assessed using the National Institutes of Health Quality Assessment Tool (NIH-QAT). A sensitivity analysis compared the effect on acute versus chronic HF populations.

Results

Twenty-six studies ($n = 1888$ patients) were included in the analyses. Based on the NIH-QAT checklist, 11 studies were at low risk of bias, 14 at moderate risk, and 1 at high risk. Meta-analysis showed that all the study drugs improved the haemodynamic variables assessed, without significant differences amongst them, except for MAP ($P = .0486$). Dobutamine and levosimendan caused a non-significant increase in MAP, while milrinone showed a trend towards a reduction in MAP [-3.46 (-7.27 to $+0.35$)]. The heterogeneity across studies was high. In the sensitivity analysis, dobutamine improved CI more than levosimendan in patients with chronic HF.

Conclusion


The use of inotropes improves haemodynamic status in patients with low-output HF, with no consistent superiority of one agent over the others. These findings support the current clinical practice of agent selection based on individual patient characteristics. Head-to-head trials in well-phenotyped HF populations are warranted to guide personalized inotrope use.

* Corresponding author. Tel: +39 091 2192111, Fax: +39 091 2192586, Email: vincenzo.nuzzi4@gmail.com

© The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Graphical Abstract



Forest plot showing the pooled effects of each drug across all included studies on the invasive haemodynamic variables analysed. Dobutamine is shown on the left, levosimendan in the centre, and milrinone on the right.

Keywords

Inotropes • Heart failure • Invasive haemodynamic • Advanced heart failure • Meta-analysis

Introduction

The medical treatment of patients with acute heart failure (HF) remains challenging with high mortality, and several clinical trials over the past decades have failed to demonstrate a survival benefit with any pharmacological intervention.¹ Indeed, while the prognosis of patients with chronic HF has recently markedly improved, the risk of in-hospital death following a hospitalization for acute HF has been unchanged in the last two decades.^{2–4} Clinical trials in this setting are particularly difficult to design, due to the marked heterogeneity of acute HF populations, challenging adherence to research protocols, including inclusion and exclusion criteria, in the acute phase and high risk of competing events.

The use of inotropes is widespread worldwide, although the evidence supporting a prognostic benefit from these drugs is still a matter of debate.⁵ Patients with acute HF often present in a low-output state leading to significant hypoperfusion of vital organs, including the heart itself, and consequent multiorgan failure.⁶ Similarly, vasodilators have a clear pathophysiological rationale in this setting, but their impact on long-term outcomes remains uncertain, highlighting the limited evidence base for both therapeutic approaches.^{7,8}

Inotropic therapy plays a pivotal role even in patients with chronic advanced HF. Indeed, haemodynamic optimization is essential in those being evaluated for advanced therapies, such as durable ventricular assist device implantation or heart transplantation.^{9,10} Also in this setting, selecting the appropriate inotropic agent remains clinically relevant and challenging.

Several mechanisms have been proposed to explain both the benefits and the harms of inotropes. The primary mechanism underlying their potential benefit is the haemodynamic improvement. Different

inotropes rely on different mechanisms of action and might exert different effects. The first inotropes used in clinical practice (dobutamine, dopamine, adrenaline) act via beta-adrenergic receptor stimulation on the cardiomyocytes leading to increased intracellular calcium concentration. On the other hand, inotropes such as levosimendan and milrinone act differently, enhancing cardiac contractility by increasing calcium sensitivity or by inhibiting phosphodiesterase III, respectively.¹¹ The magnitude of increase in cardiac function depends on the specific characteristics of each drug and on the dose administered. Understanding the expected effect on cardiac output, peripheral perfusion, cardiac filling pressures, systemic (SVR), and pulmonary vascular resistance (PVR) and circulation is crucial to individualize inotrope therapy. In addition, evidence on differences, or equivalences, amongst agents could help clinicians in the choice of the optimal drug according to other established characteristics (i.e. duration of the effect, contraindications, tolerability, costs, and availability). Therefore, we conducted a meta-analysis aiming to quantify the haemodynamic effect of dobutamine, levosimendan, and milrinone in patients with HF and low-output state.

Methods

Protocol, search strategy, and outcomes

This meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. In line with PRISMA, a PICO strategy was followed (Table 1). We focused on studies evaluating the acute haemodynamic effect of dobutamine, levosimendan and milrinone in an in-hospital setting in patients with acute

Table 1 PICOS (Population, Intervention, Comparison, Outcomes, and Study) data for formulating eligibility criteria in the meta-analysis

PICOS (Population, Intervention, Comparison, Outcomes, and Study) data for formulating eligibility criteria in the meta-analysis	
Population	Patients with heart failure and low-output
Intervention	Inotrope administration (dobutamine or levosimendan or milrinone)
Comparator	Haemodynamic status before the intervention
Outcomes	Haemodynamic improvement assessed by right heart catheterization
Setting	All Study Settings

or chronic low-output HF and reduced ejection fraction. All the patients had an indication for inotrope therapy and, therefore, were severely symptomatic (New York Heart Association class IV). The decision to focus our analyses on these drugs was based on preliminary literature research which showed that dobutamine, levosimendan and milrinone had an appropriate number of studies available. We included only studies evaluating haemodynamic variables through invasive measurement, by Swan-Ganz catheterization or right heart catheterization in the cathlab. The variables analysed were: cardiac index (CI), pulmonary artery mean pressure (PAPm), mean arterial pressure (MAP), pulmonary artery wedge pressure (PAWP), PVR, and SVR. Studies in which patients clearly received concomitant other intravenous drugs that could influence haemodynamic data were excluded. Similarly, we excluded studies on routine administration of the study drug before or after cardiac surgery/percutaneous revascularization, as well as those enrolling peculiar patient subgroups. The outcome was the quantitative within-patient change in haemodynamic variables following initiation of the study drug. When multiple haemodynamic follow-up measurements were available, the 24-hour measurement was preferred. Both observational studies and randomized clinical trials were included, but only data from patients receiving an active treatment were considered. Exclusion criteria for article selection included the following: articles not in English, review articles, meta-analyses, duplicates, unpublished data, abstracts and non-peer-reviewed articles. Only studies involving humans were considered to empower clinical relevance and applicability. A researcher (V.N.) systematically searched PubMed, OVID, Medline, Embase, and the Cochrane Library for publications before 1 February 2025. Predefined keywords and Medical Subject Headings (MeSH), including 'heart failure', 'cardiogenic shock', 'cardiac failure', 'observational study', 'cohort study', 'case-control', 'randomised clinical trial', 'right heart catheterisation', 'cardiac index', 'wedge pressure', 'inotrope', 'dobutamine', 'milrinone', 'levosimendan' and all their synonyms (Supplementary Table S1) were used. Two researchers (V.N. and C.M.) independently screened the titles and abstracts of all identified studies, selecting those of potential interest (level 1 screening). Thereafter, they examined the full text of the selected papers to finalize the selection of the study (level 2 screening) (Figure 1). Discrepancies were shared and resolved by consensus with a third reviewer (A.C.). The data extracted included: first author's name, year of publication, country, study design, patients included (acute or chronic HF), study drug administered and haemodynamic outcomes. This study did not require ethical approval or patient consent. The research protocol was registered on PROSPERO (ID: 1133068).

Quality assessment

Two researchers (V.N. and C.M.) independently evaluated the quality of the included studies using the National Institutes of Health Quality Assessment Tool (NIH-QAT), comprising 12 items. Any inconsistencies or doubts were reviewed by a third researcher (A.C.). Each study was categorized as low risk of bias (9–10 criteria met), moderate risk of bias (7–8 criteria met), or high risk of bias (<5 criteria met).

Statistical analysis

For each haemodynamic parameter (MAP, CI, mPAP, WP, PVR, SVR), the mean difference (MD) between post- and pre-treatment values was calculated for each study arm. For each haemodynamic parameter (MAP, CI, mPAP, PAWP, PVR, SVR), the MD between post- and pre-treatment values was calculated for each study arm. For paired pre-post data, the standard deviation (SD) of the change was derived from the pre- and post-treatment variability, assuming a within-patient correlation coefficient of 0.5, in line with previous meta-analyses of haemodynamic pre-post data. The standard error of the MD was then obtained by dividing the SD of the change by the square root of the sample size. Random-effects models were employed for all meta-analyses, considering the expected clinical and methodological heterogeneity across studies. Between-study heterogeneity was quantified using the I^2 statistic and τ^2 , with I^2 values of 30%, 50%, and 75% interpreted as low, moderate, and high heterogeneity, respectively. Subgroup analyses were conducted by drug class (Milrinone, Levosimendan, Dobutamine) and by study setting (acute vs chronic). Differences between subgroups were tested using χ^2 statistics. We performed additional exploratory analyses including random-effects meta-regression (REML) using available study-level covariates (baseline haemodynamic values, acute vs chronic setting, study design, inotrope dose and clinical setting), as well as influence diagnostics (studentized residuals, hat values, DFBETAs and Cook's distances), Baujat plots and leave-one-out analyses to identify influential studies. A value of $P < .05$ was considered significant. All analyses were performed with R statistical package version 4.2.2 (R Foundation).

Sensitivity analysis

To assess the robustness of our findings, multiple sensitivity analyses were performed. First, we stratified studies according to clinical setting ('acute' vs 'chronic' HF) to explore whether haemodynamic responses differed across clinical presentations. The direction and magnitude of pooled effects were consistent across settings. Second, we conducted analyses stratified by study design, comparing randomized controlled trials (RCTs) with observational studies. Despite expected differences in populations and methodological rigour, pooled haemodynamic effects remained broadly comparable, with overlapping confidence intervals and no significant subgroup interaction under the random-effects model. Third, because inotropic effects may vary by drug exposure, we performed an additional sensitivity analysis restricted to studies with clearly reported dosing regimens (including dose, bolus use, and infusion duration). Across all haemodynamic endpoints, effect estimates in this restricted dataset closely matched those of the full analysis, with minimal changes in pooled MDs and preserved directionality. Finally, studies with missing or inconsistent information required to compute standard errors (e.g. SDs or sample size) were excluded from sensitivity analyses to minimize imprecision. Overall, all sensitivity analyses confirmed the stability of the main findings, indicating that the observed haemodynamic effects were not driven by clinical setting, study design, or dosing inconsistencies.

Assessment of publication bias

Potential publication bias was evaluated for each of the six haemodynamic outcomes (CI, MAP, mPAP, PAWP, PVR and SVR). For each endpoint, we generate a dedicated funnel plot and assessed small-study effects using Egger's regression test, applied to meta-analyses including ≥ 3 studies. Funnel plot asymmetry was visually inspected, and Egger's test. P -values were used as a formal statistical measure. Analyses were performed under the same random-effects framework used for the primary models.

Results

Study selection

The initial literature research shortlisted 3785 abstracts. After removal of duplicates and screening titles and abstracts (level 1 screening), 82 papers were selected for eligibility. After reading the full text (level 2 screening), 26 papers involving 1888 patients were included in the analysis, of which 10 evaluated multiple drugs (Figure 1). Specifically, 15 papers analysed the haemodynamic effect of dobutamine, 11 focused on




Figure 1 Flowchart of the selection process for the included studies

levosimendan and 10 on milrinone. Overall, 728 patients were included in the analysis on dobutamine, 540 on levosimendan and 620 on milrinone (see [Supplementary Table S2](#) for the number of patients for specific parameters).

Study and patient characteristics

A summary of the study characteristics is reported in [Table 2](#). Eleven publications (907 patients) were from the United States of America, 3 from Canada (397 patients), 1 from China (60 patients) and 21 (524 patients) from Europe. Twenty-six cohorts included acute HF patients, and 9 evaluated patients with low-output chronic HF. Twelve papers were retrospective analyses and 14 were prospective studies. The average age of patients ranged from 54 to 75 years old.

Quality assessment results

According to the NIH-QAT evaluation of the studies included in the final analysis, 11 had a low risk of bias, 14 had a moderate risk of bias and 1 had a high risk of bias. The items less frequently met were item 3, item 5 and item 8, while the most commonly met were item 1 and item 10. A comprehensive assessment of the risk of bias is reported in [Table 3](#). Evidence certainty for all primary haemodynamic outcomes was assessed using the GRADE approach ([Supplementary Table S3](#)).

Outcomes results

Overall, all the study drugs showed a significant improvement in CI. Specifically, the magnitude of increase in CI in HF patients treated with dobutamine was $+0.76$ ($+0.62$ to $+0.89$) L/min/m², the increase in those treated with levosimendan was $+0.68$ ($+0.54$ to $+0.81$) L/min/m², and for patients treated with milrinone the improvement was $+0.68$ ($+0.53$ to $+0.84$) L/min/m². Regarding PAWP, dobutamine reduced PAWP by an average of -6.21 (-7.96 to -4.88) mmHg, levosimendan by -5.61 (-7.92 to -3.3) while the reduction in patients treated with milrinone was -8.26 (-10.60 to -5.93) (Figure 2). All the study drugs reduced mPAP. In particular, the reductions with dobutamine, levosimendan, and milrinone were -6.15 (-8.25 to -4.06) mmHg, -6.78 (-9.72 to -3.85) mmHg, and -9.57 (-15.37 to

-3.76) mmHg, respectively. Significant differences were observed in the effect on MAP according to the drug administered. Dobutamine and levosimendan caused a non-significant increase in MAP [$+1.74$ (-0.13 to $+3.61$) and $+0.36$ (-2.44 to $+3.16$) mmHg, respectively], while milrinone showed a trend towards a reduction in MAP [-3.46 (-7.27 to $+0.35$)] (Figure 3). Concerning PVR, milrinone led to a significant reduction in the values [-1.48 (-2.65 to -0.31)]. Interestingly, the administration of both dobutamine and levosimendan determined a significant reduction in PVR [-0.91 (-0.97 to -0.86) and -0.94 (-1.57 to -0.30) Woods units, respectively] as well. Finally, with all the agents investigated, a significant reduction in SVR was observed (Figure 4). There was no difference amongst the different drugs in terms of improvement in CI ($P = .658$), PAWP ($P = .230$), mPAP ($P = .551$), PVR ($P = .639$), and SVR ($P = .529$). The only haemodynamic parameter that changed significantly according to the drug tested was MAP ($P = .0486$). Overall, the heterogeneity was high for all the variables studied (I^2 from 96% to 98.8%, $P < .001$). Still, for a few specific analyses, this was low (effect of dobutamine on MAP and SVR: I^2 34.6%, $P = .152$ and I^2 0%, $P = .479$, respectively). A summary of the main results is reported in the [Graphical Abstract](#). For the primary endpoint (change in CI), none of the tested moderators significantly explained the between-study variability (all $P \geq .13$; $R^2 = 0$ –20%), and residual heterogeneity remained high ($I^2 \approx 95\%$) ([Supplementary Table S4](#)). Influence diagnostics and leave-one-out analyses did not identify any influential studies, with Cook's distances consistently below conventional thresholds and minimal variation in the pooled CI increase across models ($+0.70$ to $+0.73$ L/min/m² vs $+0.71$ L/min/m² in the main analysis) ([Supplementary Table S5](#)). For MAP, mPAP, PAWP, and PVR, baseline values significantly predicted the magnitude of change ($P \approx .0002$, $.0002$, $.0007$, and $<.0001$, respectively), explaining a relevant portion of heterogeneity ($R^2 \approx 34$ –79%), although substantial residual heterogeneity persisted ($I^2 \geq 78\%$). Baseline SVR was not significantly associated with changes in SVR ($P = .13$; [Supplementary Table S6](#)).

Sensitivity analysis

Sensitivity analyses, separately examining the potentially different effects of dobutamine, levosimendan and milrinone in patients with acute

Table 2 Main characteristics of the selected studies

First author	Year	No. of patients	Drug	Dose ($\mu\text{g/kg}/(\text{min})$)	Timing	Country	Type of study	Acute/Chronic
Abramov¹²	2017	69	Milrinone	0.375 infusion	—	USA	Observ	Chronic
Baruch¹³	2001	19	Milrinone	50 bolus	24 h	USA	Trial	Acute
Bergh¹⁴	2010	29	Levosimendan	12 (bolus) and 0.2 mcg infusion	48 h	Europe	Trial	Acute
Bergh¹⁴	2010	31	Dobutamine	5 (bolus) and 10 infusion	48 h	Europe	Trial	Acute
Charisopoulpu¹⁵	2014	22	Milrinone	50 bolus	—	UK	Observ	Chronic
Follath¹⁶	2002	103	Levosimendan	12 (bolus) and 0.1 infusion	24 h	Europe	Trial	Acute
Follath¹⁶	2002	100	Dobutamine	5	24 h	Europe	Trial	Acute
Garcia-Gonzalez¹⁷	2006	11	Levosimendan	24 (bolus) and 0.1 infusion	—	Spain	Trial	Acute
Garcia-Gonzalez¹⁷	2006	11	Milrinone	5 (staring dose)	—	Spain	Trial	Acute
Guerrero-Orriach¹⁸	2020	30	Dobutamine	5 infusion	24 h	Spain	Observ	Acute
Guerrero-Orriach¹⁸	2020	30	Levosimendan	0.1 infusion	—	Spain	Observ	Acute
Karlsberg¹⁹	1996	30	Milrinone	50 (bolus) and 0.5 infusion	24 h	USA	Trial	Acute
Karlsberg¹⁹	1996	14	Dobutamine	2.5 uptitrated to 15 infusion	24 h	USA	Trial	Acute
Kieback²⁰	1998	40	Dobutamine	—	3 h	Germany	Trial	Chronic
Lewis²¹	2018	50	Milrinone	—	3 days	USA	Observ	Acute
Lewis²¹	2018	50	Dobutamine	—	—	USA	Observ	Acute
Lilleberg²²	2006	11	Levosimendan	0.1 infusion	24 h	Finland	Trial	Chronic
Loh²³	2001	60	Milrinone	50 (bolus) and 0.5 (infusion)	—	USA	Observ	Acute
Mathew²⁴	2001	96	Dobutamine	—	24 h	Canada	Trial	Acute
Mathew²⁴	2021	96	Milrinone	—	24 h	Canada	Trial	Acute
Metra²⁵	2002	29	Dobutamine	—	—	Italy	Trial	Acute
Moerti²⁶	2005	38	Levosimendan	0.1 infusion	24 h	Austria	Trial	Acute
Mokhtari²⁷	2008	10	Dobutamine	6 infusion	24 h	Germany	Observ	Acute
Niemien²⁸	2000	95	Levosimendan	6–24 (bolus) and 0.05–0.2 infusion	24 h	Europe	Trial	Chronic
Niemien²⁸	2000	20	Dobutamine	5 infusion	24 h	Europe	Trial	Chronic
Nunez²⁹	1998	9	Milrinone	0.5 infusion	24 h	USA	Trial	Acute
Rodenas-Alesina³⁰	2023	205	Milrinone	—	—	Canada	Observ	Acute
Russ³¹	2007	56	Levosimendan	0.1 infusion	48 h	Germany	Observ	Acute
Slawsky³²	2000	98	Levosimendan	6 (bolus) and 0.1 infusion	6 h	USA	Trial	Chronic
Sun³³	2023	60	Levosimendan	12.5 mg total infusion	7 days	China	Observ	Acute
Tokuda³⁴	2005	9	Levosimendan	12 (bolus) and 0.2 infusion	24 h	Australia	Observ	Acute
Velez-Roa³⁵	2003	9	Dobutamine	10 infusion	48 h	Belgium	Trial	Chronic
Wimmer³⁶	1999	10	Dobutamine	4.5 infusion	—	Austria	Trial	Chronic
Yamani³⁷	2001	269	Dobutamine	—	—	USA	Observ	Acute
Yamani³⁷	2001	60	Levosimendan	—	—	USA	Observ	Acute

HF and chronic low-output HF, showed that CI improved more in the chronic setting when treated with dobutamine compared with the other studied drugs. Moreover, a lower heterogeneity was observed in the studies focusing on chronic low-output patients was observed (Supplementary Figures). When the analysis was restricted to studies with clearly reported dosing regimens, the pooled haemodynamic effects remained highly consistent with the main results. For CI, the pooled MD changed minimally from +0.71 L/min/m² (95% CI 0.63–0.79) in the full dataset to +0.68 L/min/m² (0.59–0.76) in the restricted dataset.

Similar concordance was observed for MAP (−0.42 [−2.23; 1.40] vs −1.07 [−3.24; 1.10]), mPAP (−7.24 [−9.31; −5.17] vs −6.09 [−7.20; −4.98]), PAWP (−6.77 [−7.96; −5.57] vs −6.58 [−8.00; −5.15]) and PVR (−1.13 [−1.59; −0.66] vs −0.82 [−0.99; −0.64]).

In all cases, confidence intervals overlapped widely and the direction of effect remained unchanged, confirming the robustness of the findings despite heterogeneous dosing information. When the analysis was stratified by study design (randomized controlled trials vs observational studies), pooled haemodynamic responses remained highly consistent (Supplementary Table S8). For CI, the pooled MD was +0.71 L/min/m² (95% CI 0.57–0.85; $k=13$) in observational studies and +0.71 L/min/m² (95% CI 0.62–0.81; $k=20$) in randomized trials (P for subgroup differences = 0.98). For mPAP, the pooled MD was −8.47 mmHg (95% CI −12.58 to −4.35; $k=7$) in observational studies and −5.99 mmHg (95% CI −6.15 to −5.82; $k=8$) in randomized trials ($P=.24$). Observational cohorts showed numerically larger reductions in PAWP, PVR and SVR (e.g. PVR −1.71 [95% CI −2.66 to −0.75] vs −0.79 Wood units [95% CI −0.98 to −0.59] in RCTs; $P=.06$), but

Table 3 Quality assessment of the studies included using the NIH-QAT

First author	Publication year	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10	Q11	Q12	Total quality score	Risk of bias
Abramov ¹²	2017	✓	✓	✓	✓	X	X	✓	X	X	✓	X	✓	7	Moderate
Baruch ¹³	2001	✓	✓	X	✓	X	✓	✓	✓	✓	✓	✓	✓	10	Low
Bergh ¹⁴	2010	✓	✓	X	✓	X	✓	✓	✓	✓	✓	X	✓	9	Low
Charisopoulpu ¹⁵	2014	✓	X	✓	✓	X	✓	✓	X	✓	✓	X	✓	8	Moderate
Follath ¹⁶	2002	✓	✓	X	✓	✓	✓	✓	X	X	✓	X	✓	8	Moderate
Garcia-Gonzalez ¹⁷	2006	✓	✓	✓	✓	X	✓	✓	X	✓	✓	✓	✓	10	Low
Guerrero-Oriach ¹⁸	2020	✓	✓	✓	✓	X	✓	✓	✓	✓	✓	X	✓	10	Low
Karlsberg ¹⁹	1996	✓	✓	✓	✓	X	X	✓	X	✓	✓	X	✓	8	Moderate
Kieback ²⁰	1998	✓	X	X	✓	X	✓	✓	X	✓	✓	X	✓	7	Moderate
Lewis ²¹	2018	✓	✓	✓	X	X	✓	X	X	✓	✓	X	✓	7	Moderate
Lilleberg ²²	2006	✓	✓	X	✓	X	✓	✓	✓	✓	✓	X	✓	9	Low
Loh ²³	2001	✓	✓	X	✓	✓	✓	✓	X	✓	✓	X	✓	9	Low
Mathew ²⁴	2021	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	12	Low
Metra ²⁵	2002	✓	✓	X	✓	X	✓	✓	X	✓	✓	✓	✓	9	Low
Moertl ²⁶	2005	✓	✓	X	✓	X	✓	✓	X	✓	✓	X	✓	8	Moderate
Mokhtari ²⁷	2008	✓	✓	X	X	X	X	X	X	✓	✓	X	✓	5	High
Niemen ²⁸	2000	✓	✓	✓	X	✓	X	✓	✓	✓	✓	✓	X	9	Low
Nunez ²⁹	1998	✓	X	X	✓	X	✓	✓	X	✓	✓	✓	✓	8	Moderate
Rodenas-Alesina ³⁰	2023	✓	✓	✓	✓	✓	X	X	X	✓	✓	X	✓	8	Moderate
Russ ³¹	2007	✓	✓	X	✓	X	X	X	X	✓	✓	X	✓	6	Moderate
Slawsky ³²	2000	✓	✓	X	✓	X	✓	✓	✓	✓	✓	✓	✓	10	Low
Sun ³³	2023	✓	✓	✓	✓	✓	X	X	X	✓	✓	X	✓	8	Moderate
Tokuda ³⁴	2005	✓	✓	✓	✓	✓	✓	✓	✓	X	✓	X	✓	10	Low
Velez-Roa ³⁵	2003	✓	X	X	X	X	✓	✓	X	✓	✓	✓	✓	7	Moderate
Wimmer ³⁶	1999	✓	✓	X	✓	X	✓	✓	X	✓	✓	✓	✓	9	Moderate
Yamani ³⁷	2001	✓	✓	X	✓	✓	✓	X	X	✓	✓	X	✓	8	Moderate

confidence intervals overlapped widely and the direction of effect remained unchanged across all endpoints (Supplementary Table S8).

Assessment of publication bias

The six funnel plots did not show relevant asymmetry, and Egger's regression tests revealed no statistically significant small-study effects (P-values ranging from .32 to .84; Supplementary Figure S7 and Supplementary Table S9).

Discussion

To our knowledge, this is the first meta-analysis to evaluate the haemodynamic effects of the most used inotropic drugs in patients with HF, providing an estimation of the magnitude of improvement achieved with dobutamine, levosimendan and milrinone. While the significant increase in CI with all three agents was expected, surprisingly, no significant differences were observed amongst the drugs in terms of CI augmentation. Furthermore, all drugs significantly reduced the PAWP, thereby improving pulmonary circulation, with associated reductions in both mPAP and PVR. Interestingly, significant differences emerged regarding their effects on MAP: levosimendan and, especially, dobutamine showed a trend towards MAP elevation, whereas milrinone slightly reduced MAP. Finally, SVR was consistently decreased following administration of each agent.

The main goal of inotropic support is to provide a clinical benefit from the established positive effect on CI. In this meta-analysis, we quantified with precision the degree of haemodynamic improvement achievable. Compared with other commonly used interventions, such as intra-aortic balloon pump (IABP), the CI increase obtained with inotropes was markedly superior. Indeed, observational studies have shown that the CI increment with IABP ranges from 0.26 L/min/m² to 0.6 L/min/m², depending on the baseline haemodynamic condition.^{38,39} This is in line with current indications to initiate inotropic therapy before mechanical circulatory support in patients with decompensated HF.⁴⁰

A noteworthy finding was the PAWP reduction observed even with dobutamine, an inotrope without a prominent vasodilator effect especially at doses ≥ 5 mcg/Kg/min and frequently used in the treatment of low cardiac output. In HF with reduced ejection fraction, pulmonary congestion is primarily driven by high PAWP, secondary to impaired LV emptying and, possibly, mitral regurgitation, rather than impaired relaxation. Dobutamine enhances cardiac LV contractility, improving emptying and, consequently, reducing LV end-diastolic pressure even in the absence of significant vasodilation on systemic or pulmonary arteries.⁴¹ As a positive consequence, pulmonary circulation improves, with a reduction in PVR and mPAP, facilitating decongestion. These findings support the clinical use of dobutamine and inotrope therapy overall in patients with diuretic-resistant congestion, to enhance renal function and diuresis.⁴² Despite the very high heterogeneity, additional random-effects meta-regression and influence analyses showed that no




Figure 2 Effects of milrinone, levosimendan, and dobutamine on cardiac index (left) and pulmonary artery wedge pressure (right). Individual and pooled mean differences shown with 95% confidence interval. Heterogeneity and P-values for each drug are reported below each panel. Overall heterogeneity and between-drug comparison P value in the bottom row.




Figure 3 Effects of milrinone, levosimendan, and dobutamine on mean pulmonary artery pressure (left) and mean arterial pressure (right). Individual and pooled mean differences shown with 95% confidence interval. Heterogeneity and P-values for each drug are reported below each panel. Overall heterogeneity and between-drug comparison P value in the bottom row.




Figure 4 Effects of milrinone, levosimendan, and dobutamine on pulmonary vascular resistance (left) and systemic vascular resistance (right). Individual and pooled mean differences shown with 95% confidence interval. Heterogeneity and *P*-values for each drug are reported below each panel. Overall heterogeneity and between-drug comparison *P* value in the bottom row.

single study drove the observed haemodynamic effects, and pooled estimates were essentially unchanged in leave-one-out analyses. Baseline haemodynamic values partially explained the variability in the magnitude of change for MAP, mPAP, PAWP, and PVR, but residual heterogeneity remained substantial, likely reflecting unmeasured clinical and methodological differences across studies. This was anticipated and reflects the variability in how these therapies are used in clinical practice. Indeed, in a global survey involving 60 countries, wide disparities in the treatment of cardiogenic shock were recorded. For example, even for dobutamine, the most widely used inotrope, there was great variability in its use as a first-line therapy, with prescription rates ranging from as low as 13% to as high as 88% across centres. Dosage regimens also varied substantially. For noradrenaline, the maximum dose was $\leq 0.15 \mu\text{g/kg/min}$ for 29% of respondents, $0.15\text{--}0.5 \mu\text{g/kg/min}$ for 53%, and $> 15 \mu\text{g/kg/min}$ for 18%.⁴³ Similarly, the parameters used to guide changes in inotropic therapy significantly vary in routine clinical practice. In a real-world survey involving 839 physicians, only 50% cited haemodynamic variables as their primary guide for reducing inotropic support, while others prioritized clinical status and side effects of inotropes.⁴⁴ Patient heterogeneity in acute HF is another key contributor to the variability in response to inotropes. The clinical scenario—whether triggered by an acute event (e.g. myocardial infarction, myocarditis, arrhythmias) or by progressive decompensation of chronic HF—may significantly influence the haemodynamic response to inotropes.⁴⁵ The underlying aetiology of LV dysfunction (ischaemic vs non-ischaemic) is also relevant. In a post-hoc analysis of a randomized clinical trial, milrinone was associated with worse outcomes in ischaemic HF, while its effect in non-ischaemic patients was neutral.⁴⁶ This heterogeneity of the acute HF setting is also reflected in our findings, as sensitivity analyses restricted to chronic low-output HF populations showed significantly lower heterogeneity. Future focused, high quality, prospective clinical trials should stratify patients according to phenotype to better assess haemodynamic responses.

The discordance between MAP and CI changes with inotrope use is clinically meaningful. Indeed, while CI invariably improved with all agents, MAP slightly declined with milrinone. This result underscores that MAP is not a reliable surrogate of tissue perfusion, which depends more directly on CI. Prior observational studies, indeed, have demonstrated that MAP is not accurate in identifying hypoperfusion, assessed via lactate levels, and is not strongly correlated with CI.^{47,48}

In the sensitivity analysis, we focused on chronic low-output HF patients, as they may require inotropes to test the reversibility of pulmonary hypertension while on the heart transplant waiting list, to prevent hospitalizations for HF, and to improve quality of life. We observed that dobutamine demonstrated greater efficacy than levosimendan in patients with chronic HF. Patients with long-standing HF are more likely to have impaired intracellular signalling, potentially diminishing the response to calcium sensitizers or phosphodiesterase inhibitors, which require intact transduction pathways to exert their effects.⁴⁹ Although inotrope-induced haemodynamic responses are dose-dependent at a pharmacological level, restricting the analysis to studies with clearly reported dosing showed that pooled effects were virtually unchanged across all endpoints. These results indicate that dosing inconsistencies did not materially influence the overall conclusions, likely reflecting the relatively narrow dosing ranges used in clinical practice and the acute nature of most haemodynamic assessments. Although the body of evidence combines randomized trials and observational cohorts, stratified analyses did not show any statistically significant modification of treatment effects by study design under a random-effects model. Haemodynamic responses were directionally concordant and of similar magnitude in RCTs and observational studies across all endpoints, suggesting that pooling these designs is unlikely to have biased the overall estimates.

In the light of the broadly comparable effect of these drugs in terms of CI increase, LV unloading and pulmonary circulation improvement, the inotrope choice in specific clinical scenarios might be guided by other factors, such as pharmacokinetics. For instance, levosimendan may be preferred for patients who would benefit from a long-acting effect without constant infusion, especially when the main aim is a reduction of the risk of HF hospitalization.⁵⁰

The apparent discordance between the positive haemodynamic effect of inotropes and the lack of beneficial effects on strong clinical outcomes (e.g. mortality) remains a matter of debate. Multiple reasons might contribute to this discrepancy, including adverse effects of inotropes, inappropriate trial design, significant variability in patient characteristics and treatment protocols. Among the adverse effects of inotropes, it has been established that both heart rate and myocardial contractility are key determinants of myocardial oxygen consumption, contributing approximately 50–70% and 15–25%, respectively.⁵¹ Moreover, the risk of arrhythmic events in patients treated with

inotropes is not negligible. A post-hoc analysis of the DOREMI trial showed that up to 47.9% of patients experienced clinically significant arrhythmic events—either supraventricular or ventricular—when treated with dobutamine or milrinone, with no significant difference between the two agents.⁵² Future clinical research should focus on improved phenotyping to identify patients most likely to benefit from active treatment, use run-in phases to exclude patients with low tolerance to these agents and incorporate biomarkers and advanced imaging, alongside invasive haemodynamic assessment, to better evaluate therapeutic efficacy.⁵³

Limitations

This study has several limitations. The high heterogeneity of the available studies limited the robustness of the results, mirroring variability both in patient characteristics and in how inotropes were administered across different settings. Detailed analyses on HF aetiology, comorbidities and concomitant beta-blocker therapy were not feasible because only a minority of the included studies provided these data. Although we were able to perform sensitivity analyses restricted to studies with clearly reported dosing regimens, a formal dose–response analysis or stratification by dose level and infusion duration could not be conducted, as dosing schemes were highly heterogeneous and many studies did not provide sufficiently granular information on inotrope titration. Additionally, studies investigating other drugs (e.g. adrenaline, dopamine, enoximone) were not numerous enough to allow meaningful comparisons. The concomitant use of other haemodynamically active drugs (vasopressor, diuretics) could not systematically be ruled out, as such treatments are often necessary in clinical practice. Lastly, although invasive haemodynamic is currently considered the gold standard, measurements may vary across centres, potentially affecting consistency.

Conclusions

Inotropic support with dobutamine, levosimendan and milrinone consistently led to improvements in invasively assessed haemodynamic parameters in patients with low-output HF. No clear superiority emerged amongst the three drugs in terms of the magnitude of haemodynamic benefit, even if in the presence of high heterogeneity, except for differences in MAP and for response to dobutamine and levosimendan in patients with chronic HF. Randomized clinical trials enrolling carefully phenotyped patients are warranted to define the specific haemodynamic response to each agent and define their prognostic effect.

Supplementary data

Supplementary data are available at [ESC Heart Failure](#) online.

Declarations

Disclosure of interest

None.

Data availability

No data were generated or analysed for this manuscript.

Funding

This study is supported by the Italian Ministry of Health-Ricerca Corrente.

Ethical approval

Ethical approval was not required.

Pre-registered clinical trial number

None supplied.

References

1. Njoroge JN, Teerlink JR. Pathophysiology and therapeutic approaches to acute decompensated heart failure. *Circ Res* 2021;**128**:1468–86. <https://doi.org/10.1161/CIRCRESAHA.121.318186>
2. Chioncel O, Mebazaa A, Maggioni AP, Harjola V, Rosano G, Laroche C, et al. Acute heart failure congestion and perfusion status—impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. *Eur J Heart Fail* 2019;**21**:1338–52. <https://doi.org/10.1002/ehf.1492>
3. Bozkurt B, Ahmad T, Alexander K, Baker WL, Bosak K, Brethett K, et al. HF STATS 2024: heart failure epidemiology and outcomes statistics an updated 2024 report from the Heart Failure Society of America. *J Card Fail* 2025;**31**:66–116. <https://doi.org/10.1016/j.cardfail.2024.07.001>
4. Tavazzi G, Tricella Garbero E, Zamperoni A, Zanetti M, Finazzi S. Cardiogenic shock in general intensive care unit: a nationwide prospective analysis of epidemiology and outcome. *Eur Heart J Acute Cardiovasc Care* 2024;**13**:768–78. <https://doi.org/10.1093/ehjacc/zuac108>
5. Bloom JE, Chan W, Kaye DM, Stub D. State of shock: contemporary vasopressor and inotrope use in cardiogenic shock. *J Am Heart Assoc* 2023;**12**:e029787. <https://doi.org/10.1161/JAHA.123.029787>
6. Arrigo M, Jessup M, Mullens VV, Reza N, Shah AM, Sliwa K, et al. Acute heart failure. *Nat Rev Dis Primers* 2020;**6**:16. <https://doi.org/10.1038/s41572-020-0151-7>
7. Mueller C, Kozhuharov N. Use of vasodilators in patients with acute heart failure: contra. *Eur Heart J Acute Cardiovasc Care* 2022;**11**:858–60. <https://doi.org/10.1093/ehjacc/zuac127>
8. Vanhentenriik S, Verbrugge FH, Tang WHW, Menon V. PRO: vasodilators remain an indispensable treatment for acute heart failure. *Eur Heart J Acute Cardiovasc Care* 2022;**11**:850–7. <https://doi.org/10.1093/ehjacc/zuac128>
9. Guglin M, Mehra S, Mason TJ. Comparison of drugs for pulmonary hypertension reversibility testing: a meta-analysis. *Pulm Circ* 2013;**3**:406–13. <https://doi.org/10.4103/2045-8932.113180>
10. Manca P, Nuzzi V, Mulè M, Sciacca S, Castrichini M, Schulz U, et al. Gaps and knowledge in the contemporary management of acute right ventricular failure. *Circ Heart Fail* 2025;**18**:e012030. <https://doi.org/10.1161/CIRCHEARTFAILURE.124.012030>
11. Francis GS, Bartos JA, Adatya S. Inotropes. *J Am Coll Cardiol* 2014;**63**:2069–78. <https://doi.org/10.1016/j.jacc.2014.01.016>
12. Abramov D, Haglund NA, Di Salvo TG. Effect of milrinone infusion on pulmonary vasculature and stroke work indices: a single-center retrospective analysis in 69 patients awaiting cardiac transplantation. *Am J Cardiovasc Drugs* 2017;**17**:335–42. <https://doi.org/10.1007/s40256-017-0225-4>
13. Baruch L, Patasil P, Hameed A, Pina I, Loh E. Pharmacodynamic effects of milrinone with and without a bolus loading infusion. *Am Heart J* 2001;**141**:14A–21A. <https://doi.org/10.1067/mhj.2001.111404>
14. Bergh C, Andersson B, Dahlström U, Forfang K, Kivikko M, Sarapohja T, et al. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers. *Eur J Heart Fail* 2010;**12**:404–10. <https://doi.org/10.1093/eurjhf/hfq032>
15. Charisopoulou D, Leaver N, Banner NR. Milrinone in advanced heart failure: dose and therapeutic monitor outside intensive care unit. *Angiology* 2014;**65**:343–9. <https://doi.org/10.1177/0003319713485808>
16. Foilath F, Cleland J, Just H, Papp J, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. *Lancet* 2002;**360**:196–202. [https://doi.org/10.1016/S0140-6736\(02\)09455-2](https://doi.org/10.1016/S0140-6736(02)09455-2)
17. García-González MJ, Domínguez-Rodríguez A, Ferrer-Hita JJ, Abreu-González P, Muñoz MB. Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. *Eur J Heart Fail* 2006;**8**:723–8. <https://doi.org/10.1016/j.ejheart.2006.01.007>
18. Guerrero-Orriach JL, Malo-Manso A, Ramirez-Aliaga M, Florez Vela AI, Galán-Ortega M, Moreno-Cortes I, et al. Renal and neurologic benefit of levosimendan vs dobutamine in patients with low cardiac output syndrome after cardiac surgery: clinical trial FIM-BGC-2014-01. *Front Pharmacol* 2020;**11**:1331. <https://doi.org/10.3389/fphar.2020.01331>
19. Karlsberg RP, DeWood MA, DeMaria AN, Berk MR, Lasher KP; For The Milrinone-Dobutamine Study Group. Comparative efficacy of short-term intravenous

- infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. *Clin Cardiol* 1996;**19**:21–30. <https://doi.org/10.1002/clc.4960190106>
20. Kieback AG, Iven H, Stolzenburg K, Baumann G. Saterinone, dobutamine, and sodium nitroprusside: comparison of cardiovascular profiles in patients with congestive heart failure. *J Cardiovasc Pharmacol* 1998;**32**:629–36. <https://doi.org/10.1097/00005344-199810000-00016>
 21. Lewis TC, Aberle C, Altschuler D, Piper GL, Papadopoulos J. Comparative effectiveness and safety between milrinone or dobutamine as initial inotrope therapy in cardiogenic shock. *J Cardiovasc Pharmacol Ther* 2019;**24**:130–8. <https://doi.org/10.1177/1074248418797357>
 22. Lilleberg J, Laine M, Palkama T, Kivikko M, Pohjanjousi P, Kupari M. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. *Eur J Heart Fail* 2007;**9**:75–82. <https://doi.org/10.1016/j.ejheart.2006.04.012>
 23. Loh E, Elkayam U, Cody R, Bristow M, Jaski B, Colucci WS. A randomized multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerin in patients with advanced heart failure. *J Card Fail* 2001;**7**:114–21. <https://doi.org/10.1054/jcaf.2001.24136>
 24. Mathew R, Di Santo P, Jung RG, Marbach JA, Hutson J, Simard T, et al. Milrinone as compared with dobutamine in the treatment of cardiogenic shock. *N Engl J Med* 2021;**385**:516–25. <https://doi.org/10.1056/NEJMoa2026845>
 25. Metra M, Nodari S, D'Aloia A, Muneretto C, Robertson AD, Bristow MR, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure. *J Am Coll Cardiol* 2002;**40**:1248–58. [https://doi.org/10.1016/S0735-1097\(02\)02134-4](https://doi.org/10.1016/S0735-1097(02)02134-4)
 26. Moertl D, Berger R, Huelsmann M, Bojic A, Pacher R. Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure. *Eur J Heart Fail* 2005;**7**:1156–63. <https://doi.org/10.1016/j.ejheart.2005.05.001>
 27. Korelitz BI, Sommers SC. Responses to drug therapy in ulcerative colitis. Evaluation by rectal biopsy and histopathological changes. *Am J Gastroenterol* 1975;**64**:365–70.
 28. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. *J Am Coll Cardiol* 2000;**36**:1903–12. [https://doi.org/10.1016/S0735-1097\(00\)00961-X](https://doi.org/10.1016/S0735-1097(00)00961-X)
 29. Colucci WS, Wright RF, Jaski BE, Fifer MA, Braunwald E. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness. *Circulation* 1986;**73**:III175–83.
 30. Rodenas-Alesina E, Luis Scolari F, Wang VN, Brahmabhatt DH, Mihajlovic V, Fung NL, et al. Improved mortality and haemodynamics with milrinone in cardiogenic shock due to acute decompensated heart failure. *ESC Heart Fail* 2023;**10**:2577–87. <https://doi.org/10.1002/ehf2.14379>
 31. Russ MA, Prondzinsky R, Christoph A, Schlitt A, Buerke U, Söffker G, et al. Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. *Crit Care Med* 2007;**35**:2732–9. <https://doi.org/10.1097/01.CCM.0000287524.17358.48>
 32. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. *Circulation* 2000;**102**:2222–7. <https://doi.org/10.1161/01.CIR.102.18.2222>
 33. Sun X, Wei C, Li L, Qu C. Levosimendan improves cardiac function, hemodynamics, and body inflammation in patients with acute myocardial infarction and heart failure. *Am J Transl Res* 2023;**15**:5624–32.
 34. Tokuda Y, Grant PW, Wolfenden HD, Manganas C, Lyon WJ, Murala JSK. Levosimendan for patients with impaired left ventricular function undergoing cardiac surgery. *Interact Cardiovasc Thorac Surg* 2006;**5**:322–6. <https://doi.org/10.1510/icvts.2005.122390>
 35. Velez-Roa S, Renard M, Degaute JP, Van De Borne P. Peripheral sympathetic control during dobutamine infusion. *J Am Coll Cardiol* 2003;**42**:1605–10. <https://doi.org/10.1016/j.jacc.2003.07.004>
 36. Wimmer A, Stanek B, Kubecova L, Vitovec J, Spinar J, Yilmaz N, et al. Effects of prostaglandin E1, dobutamine and placebo on hemodynamic, renal and neurohumoral variables in patients with advanced heart failure. *Jpn Heart J* 1999;**40**:321–34. <https://doi.org/10.1536/jhj.40.321>
 37. Yamani MH, Haji SA, Starling RC, Kelly L, Albert N, Knack DL, et al. Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: hemodynamic efficacy, clinical outcome, and economic impact. *Am Heart J* 2001;**142**:998–1002. <https://doi.org/10.1067/mhj.2001.119610>
 38. Fried JA, Nair A, Takeda K, Clerkin K, Topkara VK, Masoumi A, et al. Clinical and hemodynamic effects of intra-aortic balloon pump therapy in chronic heart failure patients with cardiogenic shock. *J Heart Lung Transplant* 2018;**37**:1313–21. <https://doi.org/10.1016/j.healun.2018.03.011>
 39. Kalapurakal G, Chau VQ, Imamura T, Tolia S, Sciamanna C, Macaluso GP, et al. Haemodynamic effects of intra-aortic balloon pumps stratified by baseline pulmonary artery pulsatility index. *ESC Heart Fail* 2025;**12**:316–25. <https://doi.org/10.1002/ehf2.15083>
 40. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2021;**42**:3599–726. <https://doi.org/10.1093/eurheartj/ehab368>
 41. Nagy L, Pollesello P, Papp Z. Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus. *J Cardiovasc Pharmacol* 2014;**64**:199–208. <https://doi.org/10.1097/FJC.0000000000000113>
 42. Gustafsson F, Damman K, Nalbantgil S, Van Laake LW, Tops LF, Thum T, et al. Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2023;**25**:457–68. <https://doi.org/10.1002/ehf.2814>
 43. Tavazzi G, Rossello X, Grand J, Gierlotka M, Sionis A, Ahrens I, et al. Epidemiology, monitoring, and treatment strategy in cardiogenic shock. A multinational cross-sectional survey of ESC-acute cardiovascular care association research section. *Eur Heart J Acute Cardiovasc Care* 2022;**11**:706–11. <https://doi.org/10.1093/ehjacc/zuac087>
 44. Scheeren TWL, Bakker J, Kaufmann T, Annane D, Asfar P, Boerma EC, et al. Current use of inotropes in circulatory shock. *Ann Intensive Care* 2021;**11**:21. <https://doi.org/10.1186/s13613-021-00806-8>
 45. Chioncel O, Mebazaa A, Harjola V, Coats AJ, Piepoli MF, Crespo-Leiro MG, et al. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. *Eur J Heart Fail* 2017;**19**:1242–54. <https://doi.org/10.1002/ehf.890>
 46. Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, Califf RM, et al. Heart failure etiology and response to milrinone in decompensated heart failure. *J Am Coll Cardiol* 2003;**41**:997–1003. [https://doi.org/10.1016/S0735-1097\(02\)02968-6](https://doi.org/10.1016/S0735-1097(02)02968-6)
 47. Hamzaoui O, Boissier F. Hemodynamic monitoring in cardiogenic shock. *J Intensive Med* 2023;**3**:104–13. <https://doi.org/10.1016/j.jointm.2022.10.003>
 48. Levy B, Curtiaud A, Duarte K, Delmas C, Demissele J, Girerd N, et al. Association between mean hemodynamic variables during the first 24 h and outcomes in cardiogenic shock: identification of clinically relevant thresholds. *Crit Care* 2025;**29**:137. <https://doi.org/10.1186/s13054-025-05356-0>
 49. Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac energy metabolism in heart failure. *Circ Res* 2021;**128**:1487–513. <https://doi.org/10.1161/CIRCRESAHA.121.318241>
 50. Antila S, Sundberg S, Lehtonen LA. Clinical pharmacology of levosimendan. *Clin Pharmacokinet* 2007;**46**:535–52. <https://doi.org/10.2165/00003088-200746070-00001>
 51. Duncker DJ, Bache RJ. Regulation of coronary blood flow during exercise. *Physiol Rev* 2008;**88**:1009–86. <https://doi.org/10.1152/physrev.00045.2006>
 52. Jung RG, Di Santo P, Mathew R, Simard T, Parlow S, Weng W, et al. Arrhythmic events and mortality in patients with cardiogenic shock on inotropic support: results of the DOREMI randomized trial. *Can J Cardiol* 2023;**39**:394–402. <https://doi.org/10.1016/j.cjca.2022.09.013>
 53. Ahmad T, Miller PE, McCullough M, Desai NR, Riello R, Psotka M, et al. Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials. *Eur J Heart Fail* 2019;**21**:1064–78. <https://doi.org/10.1002/ehf.1557>